The impact of the “4+7” volume-based procurement policy in the pharmaceutical field on the high-value bone and joint consumables market

At the current time point, the expectation gap of the centralized procurement policy and the promotion of mid-term performance events will further change the bone and joint market of high-value consumables. At present, the insufficient productivity of orthopedic medical devices is still a big problem.

The annual compound growth rate of the orthopedic market exceeds 15%

According to public data, in recent years, with the advancement of my country's medical technology level, the enhancement of medical insurance and personal payment ability, and the aggravation of the aging of the population, the treatment demand in my country's orthopedic market has been rapidly released, with an annual compound growth rate of about 15% or more.

At present, domestic orthopedic implant consumables manufacturers continue to promote product innovation and technological upgrading, and the market share of domestic orthopedic consumables manufacturers has further increased.

Last year, the introduction of the "4+7" volume-based procurement policy in the pharmaceutical field, the implementation of medical insurance cost control, and the two-ticket system in the field of high-value consumables were piloted in some provinces and cities, which had a great impact on the future development of the high-value consumables industry.

In mid-July, the National Medical Insurance Administration held a symposium on the 4+7 centralized procurement, and many companies participated. Judging from the content of the meeting, it has been determined that the centralized procurement work will be linked on a large scale. It should be noted that the centralized procurement has changed from one winning bid to three winning bids, which shows that the centralized procurement policy is becoming more moderate.

At present, orthopedic joint-related products are a sub-category of orthopedic implants. Due to the properties of non-standard products, it is difficult to conduct national centralized procurement.